Interested in an ASX Blue Chip Stock? Explore CSL Ltd (ASX:CSL) Share Price

September 13, 2024 05:16 PM AEST | By Team Kalkine Media
 Interested in an ASX Blue Chip Stock? Explore CSL Ltd (ASX:CSL) Share Price
Image source: megapixel

The share price of CSL Ltd, an ASX blue chip stock, has risen by 4.1% since the beginning of 2024, while Pro Medicus Ltd is currently just 1.1% shy of its 52-week high. This article delves into why both CSL and Pro Medicus could be interesting additions to an ASX investing watchlist. 

CSL Share Price (ASX:CSL) 

CSL is a global biotechnology leader, known for developing and delivering innovative medicines aimed at improving lives, protecting public health, and supporting individuals with life-threatening medical conditions. The company operates through three major divisions: 

- CSL Behring: Focuses on the manufacturing and distribution of blood plasma products. This division was acquired in 2004 and continues to play a significant role in CSL's portfolio. 

- CSL Seqirus: Formed by the rebranding of BioCSL and the acquisition of Novartis' flu business in 2015, Seqirus specializes in flu vaccines and pandemic-related services, often working with government bodies. 

- CSL Vifor: Provides products that target iron deficiency and renal care, further expanding the company’s reach in the healthcare industry. 

CSL has established itself as a reliable company for Australian investors, especially given its consistent dividend payouts over the years. Many view an investment in CSL as a way to indirectly benefit from the rising costs of global healthcare, particularly as demand for specialized medical treatments continues to grow. 

Pro Medicus Shares in Focus (ASX:PME) 

Founded in 1983, Pro Medicus Ltd is a global leader in radiology IT software, providing innovative solutions to hospitals, imaging centers, and healthcare groups worldwide. The company’s core product offerings include:

- Radiology Information Systems (RIS): Supports the management of medical imaging operations, including patient scheduling and billing. 

- Picture Archiving and Communication Systems (PACS): Enables healthcare providers to store, retrieve, and share medical images efficiently. 

- Visage Software: Pro Medicus' flagship product that allows radiologists to view large medical image files remotely on mobile devices. This technology facilitates faster and more accurate diagnostic decisions, ideally leading to improved patient outcomes. 

Pro Medicus has garnered global attention due to its ability to streamline radiology workflows and improve patient care through advanced visualization and mobile diagnostic solutions. 

CSL Share Price Valuation 

One way to gauge CSL’s current share price is by examining its dividend yield over time. The dividend yield represents the return a shareholder receives in the form of dividends, though it can vary based on payments and share price changes. At present, CSL shares offer a dividend yield of 1.32%, slightly below the company’s 5-year average yield of 1.50%. This indicates that CSL shares are currently trading at a level below their historical average in terms of dividend yield. 

Both CSL Ltd and Pro Medicus Ltd are noteworthy ASX healthcare stocks, with CSL recognized for its consistent dividend payouts and leadership in biotechnology, and Pro Medicus known for its innovative radiology IT solutions. As the global healthcare sector continues to grow, these two companies could present interesting opportunities for investors to monitor. 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.


AU_advertise

Advertise your brand on Kalkine Media

Sponsored Articles


Investing Ideas

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.